Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Neuromodulation Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 111 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 111 pages
- Published: 12-06-2019
Market Overview
Neurological diseases are frequent in older adults, affecting around 55% of people age 55 and older. They are associated with a high risk for adverse health outcomes, including mortality, disability, institutionalization, and hospitalization. Degenerative diseases, like dementia and Parkinson’s disease, as well as strokes and headaches, are frequently encountered neurological diseases in elderly patients. Neuromodulation is an intracranial, electrical neuromodulation therapy that has FDA approval for the treatment for most of the neurological diseases such as bladder control, headache, tremors, chronic pain, stroke, minimally conscious state, and spinal cord injury, which are most commonly found in the elderly population. The proven efficacy and improving acceptance of this technology are expected to lead to the surge in the market demand during the forecast period.
Scope of the Report
Neuromodulators are a subset of neurotransmitter. Unlike neurotransmitters, the release of neuromodulators occurs in a diffuse manner. This means that an entire neural tissue may be subject to the neuromodulator’s action due to exposure. This, in turn, can tune the neural circuitry of an entire brain region and not just that of an individual neuron.
Key Market Trends
Spinal Cord Stimulation (SCS) Holds the Largest Market Share in the Internal Neuromodulation Type
The process of numbing/reducing chronic pain by passing continuous low voltage electric current to the spinal cord is referred to as spinal cord stimulation (SCS). The SCS devices are FDA approved and are the most widely accepted neurostimulation techniques across the world. These devices are of basic three types namely, rechargeable, conventional, and radiofrequency systems. SCS is used in neurological problems, such as nerve damage, arachnoiditis, failed-back surgery syndrome, neuropathy, complex regional pain syndrome, and neuritis. Along with the associated benefits and effectiveness, SCS also has some pitfalls, such as overstimulation, intermittent stimulation, lead dispositioning, and device malfunctioning. However, the benefits of the SCS outrank the pitfalls, thus boosting the segment’s growth over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall neuromodulation market with the United States accounting as the major contributor to the market. The presence of major market players and huge pharmaceutical and biopharmaceutical industries, coupled with the rising investments in the country for the adoption of advanced technologies, is expected to boost the regional growth of the market over the forecast period. In addition, the rising concern about the prevalence of neurological disorder and other associated disorders is stimulating the need for the adoption of neuromodulation techniques. Asia-Pacific, on the other hand, is expected to grow with the fastest growth rate over the forecast period.
Competitive Landscape
The major market players in the market include Medtronic PLC, Boston Scientific Corporation, St. Jude Medical Inc., Synapse Biomedical Inc., and Nevro Corporation, among others. The increasing innovation and rise in investment for various public and private organizations are expected to intensify the industry rivalry across the world.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Neurological Disorders
4.2.2 Increase in the Aging Population
4.2.3 Strong Product Pipeline
4.2.4 Expanded Target Applications and New Indications
4.2.5 Growing Investments
4.3 Market Restraints
4.3.1 Inconsistent Reimbursement Policies
4.3.2 Lack of Trained Professionals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Internal Neuromodulation
5.1.1.1 Spinal Cord Stimulation (SCS)
5.1.1.2 Deep Brain Stimulation (DBS)
5.1.1.3 Vagus Nerve Stimulation (VNS)
5.1.1.4 Sacral Nerve Stimulation (SNS)
5.1.1.5 Gastric Electrical Stimulation (GES)
5.1.2 External Neuromodulation (Non-Invasive)
5.1.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
5.1.2.2 Transcranial Magnetic Stimulation (TMS)
5.1.2.3 Respiratory Electrical Stimulation (RES)
5.2 By Application
5.2.1 Parkinson’s disease
5.2.2 Depression
5.2.3 Chronic Pain
5.2.4 Failed Back Surgery
5.2.5 Ischemia
5.2.6 Urine Incontinence
5.2.7 Fecal Incontinence
5.2.8 Epilepsy
5.2.9 Gastroparesis
5.2.10 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Medtronic PLC
6.1.2 Boston Scientific Corporation
6.1.3 St. Jude Medical Inc.
6.1.4 Synapse Biomedical Inc.
6.1.5 Nevro Corporation
6.1.6 Neurosigma Inc.
6.1.7 Neuropace Inc.
6.1.8 Neuronetics Inc.
6.1.9 Cyberonics Inc.
6.1.10 BioControl Medical
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Internal Neuromodulation
Spinal Cord Stimulation (SCS)
Deep Brain Stimulation (DBS)
Vagus Nerve Stimulation (VNS)
Sacral Nerve Stimulation (SNS)
Gastric Electrical Stimulation (GES)
External Neuromodulation (Non-Invasive)
Transcutaneous Electrical Nerve Stimulation (TENS)
Transcranial Magnetic Stimulation (TMS)
Respiratory Electrical Stimulation (RES)
By Application
Parkinson’s disease
Depression
Chronic Pain
Failed Back Surgery
Ischemia
Urine Incontinence
Fecal Incontinence
Epilepsy
Gastroparesis
Other Applications
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Neurology Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the growth of the market are the increasing incidence of neurological disorders, huge investments by private players in neurology devices, increase in R&D in the field of neurotherapies, and rising aging population.
The growth of the global neurology devices market is attributed to the increasing incidence of neurological disorders that include brain aneurysms, brain tumors, epilepsy, memory disorders, multiple sclerosis, Parkinson’s disease, peripheral neuropathy, post-herpetic neuralgia, spinal cord tumor, and stroke.
The increasing healthcare spending, increasing foreign direct investment by global medical device manufactures, and increasing neurological disease prevalence are expected to drive the overall market growth.
Scope of the Report
As per the scope of the report, neurological devices are medical devices that help to diagnose, prevent, and treat a variety of neurological disorders and conditions, such as Alzheimer’s disease, Parkinson’s disease, major depression, and traumatic brain injury. The growth of neurological devices is being driven through an emphasis on developing superior neuromodulation and neurostimulation techniques, leveraging minimally invasive procedures that benefit patients. This has resulted in companies investing more in R&D, in an effort to better treat and rehabilitate the brain.
Key Market Trends
Sacral Nerve Stimulation Devices is the Segment under Neurostimulation Devices that is Expected to Grow Fastest during the Forecast Period
The sacral nerve stimulation devices are mostly used for patients for whom drug therapy or other types of medications are not successful. It is performed with the help of a small device, which is capable of sending electrical impulses to the targeted sacral nerves located in the lower back region. These devices are found to be successful in treating bladder problems. Hence, with increasing incidences of overactive bladder, the sacral nerve stimulation devices segment is expected to grow during the forecast period.
The deep brain stimulation devices are also being used to perform deep brain stimulation procedures, by implanting a medical device that is capable of sending electrical impulses to specific target areas in the brain. These devices are generally used to treat neuropsychiatric disorders and are effectively used in treating various other neurological disorders, like Parkinson’s disease, essential tremor, dystonia, chronic pain, major depression, and obsessive-compulsive disorder.
Asia-Pacific Registered the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period
The Asia-Pacific region is expected to grow, due to the presence of high unmet medical needs, coupled with rapidly rising healthcare R&D investments and growing medical expenditures in emerging economies, such as India and China. There are also a number of government initiatives that are expected to increase over the forecast period.
Competitive Landscape
There are market participants involved in R&D for the development of advanced stimulation and neuromodulation techniques with minimally invasive procedures that are more preferable to the patients. Furthermore, many private companies are showing great interest in developing novel neurological devices to earn huge profits.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Incidence of Neurological Disorders
4.2.2 Huge Investments by Private Players in Neurology Devices
4.2.3 Increase in R&D in the Field of Neurotherapies
4.2.4 Rise in the Aging Population
4.3 Market Restraints
4.3.1 High Cost of Equipment
4.3.2 Stringent FDA Validation and Guidelines for New Devices
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type of Device
5.1.1 Cerebrospinal Fluid Management Devices
5.1.2 Interventional Neurology Devices
5.1.2.1 Interventional/Surgical Simulators
5.1.2.2 Neurothrombectomy Devices
5.1.2.3 Carotid Artery Stents
5.1.2.4 Embolic Coils
5.1.2.5 Support Devices
5.1.3 Neurosurgery Devices
5.1.3.1 Neuroendoscopes
5.1.3.2 Stereotactic Systems
5.1.3.3 Aneurysm Clips
5.1.3.4 Other Neurosurgery Devices
5.1.4 Neurostimulation Devices
5.1.4.1 Spinal Cord Stimulation Devices
5.1.4.2 Deep Brain Stimulation Devices
5.1.4.3 Sacral Nerve Stimulation Devices
5.1.4.4 Other Neurostimulation Devices
5.1.5 Other Types of Devices
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 Boston Scientific Corporation
6.1.3 Stryker Corporation
6.1.4 Medtronic PLC
6.1.5 Abbott Laboratories
6.1.6 Johnson and Johnson
6.1.7 Smith & Nephew
6.1.8 MicroPort Scientific Corporation
6.1.9 Nihon Kohden Corporation
6.1.10 Penumbra Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type of Device
Cerebrospinal Fluid Management Devices
Interventional Neurology Devices
Interventional/Surgical Simulators
Neurothrombectomy Devices
Carotid Artery Stents
Embolic Coils
Support Devices
Neurosurgery Devices
Neuroendoscopes
Stereotactic Systems
Aneurysm Clips
Other Neurosurgery Devices
Neurostimulation Devices
Spinal Cord Stimulation Devices
Deep Brain Stimulation Devices
Sacral Nerve Stimulation Devices
Other Neurostimulation Devices
Other Types of Devices
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Netherlands In-Vitro Diagnostics Market – Growth, Trends & Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 75 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 75 pages
- Published: 07-06-2019
Market Overview
The Netherlands in vitro diagnostics market is expected to register a CAGR of approximately 5.3% over the forecast period. Major factors that are fueling this market include rapid increase in chronic diseases, increasing demand for point-of-care testing and personalized medicine, and technological advances, along with the rising geriatric population in the country.
As per a report of National Institute of Health (NIH), incidences and prevalence of chronic diseases are rapidly increasing across the world and are currently affecting more than 14 million people around the world. Furthermore, according to the World Health Organization, the prevalence rate of the overweight population in the Netherlands was 67% for men and 59% for women in 2016, and this rate is expected to increase in the coming years.
According to the European Diagnostic Manufacturers Association (EDMA), the cost of IVDs to the European healthcare systems is less than EUR 21 per person per year. In addition, patients can deal with their conditions better with the help of IVDs (diabetic patients can use portable blood glucose monitors on a regular basis to determine their blood glucose level). Therefore, the demand for IVD products is influenced by the increase in incidences of chronic diseases. As the demand for IVD is increasing, the market is growing at a faster pace.
Scope of the Report
IVDs are tests performed in laboratories or by consumers at homes, to diagnose, monitor, screen, and assess various diseases, conditions, or infections. IVD products are reagents, instruments, and systems that are intended for use in the diagnosis of diseases or other conditions. IVDs form an essential part of the current healthcare system. They reduce hospital stays and the need to recuperate.
Key Market Trends
The Point-Of-Care Diagnostics Segment is Expected to Experience the Highest CAGR Over the Forecast Period
The point-of-care (PoC) diagnostics segment of the Netherlands in vitro diagnostics market is expected to register the highest CAGR during the forecast period.
There is a significant demand for PoC diagnostics that can provide accurate and directional results. These PoC tests allow healthcare providers to begin essential treatment during visits. Many nucleic acids and immunoassay-based PoC diagnostic devices are coming close to commercialization.
Earlier, the lack of an efficient reimbursement system for the PoC technology led to the absence of both niche markets and entrepreneurial activities by large manufacturers. Hence, the Dutch government has now actively stimulated the primary diagnostic system by implementing new guidelines and lobbies. This triggered consolidation processes, entrepreneurial activities, the diagnostic market, and the performance of the IVD innovation system.
Hence, owing to the support of the government, along with the significance of PoC, the segment is expected to experience growth faster.
Competitive Landscape
The Netherlands in vitro diagnostics market has several key players, such as Roche Diagnostics, Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, and Thermo Fisher Scientific Inc., who hold large shares in this market. However, with the help of product innovation and technological advances, there is a possibility of new players entering the market in the future.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rapid Increase in Chronic Diseases
4.2.2 Increasing Number of Private Hospitals and Independent Testing Laboratories
4.2.3 Increasing Demand for Point-of-Care Testing and Personalized Medicine
4.2.4 Technological Advances along with Rising Geriatric Population
4.3 Market Restraints
4.3.1 Price Concern
4.3.2 Stringent Regulatory Framework
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Clinical Chemistry
5.1.2 Immunoassays
5.1.3 Hematology
5.1.4 Coagulation and Hemostasis
5.1.5 Microbiology
5.1.6 Point-of-Care Diagnostics
5.1.7 Molecular Diagnostics
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Data Management Systems and Services
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By End User
5.4.1 Hospitals and Clinics
5.4.2 Laboratories
5.4.3 Academics
5.4.4 Point-of-Care Testing
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson and Company
6.1.3 Bio-Rad Laboratories Inc.
6.1.4 Danaher Corporation
6.1.5 Johnson & Johnson
6.1.6 Roche Diagnostics
6.1.7 Siemens Healthcare
6.1.8 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Clinical Chemistry
Immunoassays
Hematology
Coagulation and Hemostasis
Microbiology
Point-of-Care Diagnostics
Molecular Diagnostics
By Product
Instrument
Reagent
Data Management Systems and Services
By Usability
Disposable IVD Devices
Reusable IVD Devices
By End User
Hospitals and Clinics
Laboratories
Academics
Point-of-Care Testing
Nebulizer Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global nebulizer market was valued at USD 862.75 million in 2018, and it is estimated to value at USD 1,255.33 million by 2024, while witnessing a CAGR of 6.45% during the forecast period, 2019-2024. There are certain factors that are driving the market growth, including rising incidences of chronic respiratory diseases, increasing demand for home healthcare devices, and rising geriatric population base.
Nebulizers are respiratory drug delivery devices that transform liquid medications into aerosols (liquid particles in a gas). The drug is converted into a mist that can be directly delivered to the patient’s lungs. The rising incidences of chronic respiratory diseases and rapid technological advances are among the key factors driving the usage of nebulizers.
The adoption is also increasing, due to the demand for new technologies with higher quality, smaller size, lighter weight, and ease of accessibility, by the patients.
Thus, the increasing demand for home healthcare devices is driving the growth of the market studied.
Scope of the Report
Nebulizer is a medical device that converts the drug into mist and delivers it directly to the lungs. The technique of nebulization is commonly used for the treatment of respiratory diseases, including asthma, cystic fibrosis, and COPD. There are various devices that can be used for nebulization. Some of the devices are rechargeable, and electrically powered ones are the most widely used.
Key Market Trends
Mesh Nebulizer Segment is Expected to Hold the Largest Market Share
The mesh nebulizer segment of the global nebulizer market is expected to witness a high CAGR of 7.60% over the forecast period.
Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Thus it was estimated that mesh nebulizers will be increasingly adopted in the coming future. This is due to the portability, convenience, and speed of treatment, owing to their low residual volumes and accurate lung delivery. Thus, technological advancements in mesh nebulizers, with the development of an innovative solution, are likely to further drive the growth of the market in the future.
There has also been a rising adoption of portable nebulizers by patients, which is contributing toward the market growth. Portable nebulizers are expected to witness robust growth, owing to the ease and convenience of use, technological advancement in devices, and launch of several new products in recent years.
North America Dominates the Market and is Expected to do so over the Forecast Period
The North American nebulizer market is growing, due to the continuous innovations in technology. As the population in the region follows a fast-moving lifestyle, patients are looking for more portable nebulizer devices that can be transferred easily in time of need for patients suffering from asthma and other airway diseases.
In addition, healthcare cost containment issues, post economic crisis in the United States, have required the government to introduce new strategies to reduce patient stays in hospitals. This provided impetus to homecare services, which in turn, created a favorable environment for the growth of the nebulizer market.
Competitive Landscape
The global nebulizer market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, various strategies, such as mergers and acquisitions, product approvals, and agreements, are being adopted by these key market players to increase the outreach of their products and strengthen their product portfolios. The major players are Agilent Technologies Becton, Dickinson and Company, and GF Health Products Inc.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Chronic Respiratory Diseases
4.2.2 Increasing Demand for Home Healthcare Devices
4.2.3 Rising Geriatric Population Base
4.3 Market Restraints
4.3.1 Drug Loss during Drug Delivery
4.4 Industry Attractiveness Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Pneumatic Nebulizer
5.1.2 Ultrasonic Nebulizer
5.1.3 Mesh Nebulizer
5.2 By Portability
5.2.1 Tabletop Nebulizer
5.2.2 Portable Nebulizer
5.3 Sales Channel
5.3.1 Direct Purchase
5.3.2 Online Purchase
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Becton Dickinson and Company
6.1.3 Briggs Healthcare
6.1.4 Drive DeVilbiss Healthcare
6.1.5 GF Health Products Inc.
6.1.6 Invacare Corporation
6.1.7 Koninklijke Philips NV
6.1.8 Medline Industries Inc.
6.1.9 Omron Corporation
6.1.10 PARI Pharma
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Pneumatic Nebulizer
Ultrasonic Nebulizer
Mesh Nebulizer
By Portability
Tabletop Nebulizer
Portable Nebulizer
Sales Channel
Direct Purchase
Online Purchase
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Molecular Diagnostics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The global molecular diagnostics market was valued at USD 7,854.45 million in 2018, and is estimated to be valued at USD 13,340.35 million by 2024, while witnessing a CAGR of 9.23% during the forecast period, 2019-2024. Factors that are responsible for the growth of the market include large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, recent advancements in pharmacogenomics, and rapidly evolving technology.
Molecular diagnostics is considered to be the best method to identify and characterize a microorganism. An effective test must be precise, rapid, and also be able to measure the infectious burden. Better testing quickly identifies the organism’s strain and drug susceptibility, thus, reducing the delay in finding the right antibiotic. Technological advancements, like a polymerase chain reaction (PCR), have also made it possible to identify the antimicrobial resistance genes and provide public health information, such as strain characterization by genotyping. The infectious disease segment currently records the highest growth in the molecular diagnostics market.
Scope of the Report
Molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphisms (SNP), deletions, rearrangements, insertions, and others), which may or may not be associated with diseases. Molecular diagnostics has been revolutionized over the past few decades. Currently, it is the driving force behind the transformation in healthcare, thus, leading to innovations in the field of molecular biology. These include next-generation sequencing, microarray technologies, liquid biopsies, early cancer detection, direct-to-consumer testing, and point-of-care assays.
Key Market Trends
Instruments Sub-segment is Expected to Hold the Largest Market Share in the Product Segment
In the product segment of the global molecular diagnostics market, the instruments sub-segment is believed to have the largest market size and is expected to witness a CAGR of 9.13% during the forecast period.
Molecular diagnostics plays a vital role in the assessment of disease prognosis and therapy response, as well as in the detection of minimal residual disease. In the past decade, molecular diagnostics has grown, due to advances in the chemistries and instrumentation, including automation, integration, throughput, and the ability to use the instrumentation in a random-access mode.
Some of the sophisticated instruments used in this market are High-performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR), along with real-time PCR, Enzyme-linked ImmunoSorbent Assay (ELISA), RadioImmunoAssay (RIA), lateral flow devices, patient safety syringes, point-of-care testing devices, and others.
North America Dominates the Market and is Expected to do the Same over the Forecast Period
North America currently dominates the molecular diagnostics market and is expected to continue its stronghold for a few more years. The United States accounts for the largest market share in the overall North American molecular diagnostics market. Molecular diagnostics has played a vital role in changing the face of disease diagnostics and assuring speedy detection and accurate care for critically ill patients. The increase in per capita health expenditures, the advancement in healthcare infrastructure, and the increase in the number of infectious diseases and cancer cases in the United States have led to a shift in trend from the traditional diagnostic methods to molecular diagnostics.
In addition, rising technological advancements, increasing entry of new players, and speedy adoption of advanced molecular diagnostics, are helping in the growth of the market in the United States.
Competitive Landscape
The global molecular diagnostics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to small companies are increasing their market presence by introducing new devices with fewer prices. Companies, like Abbott Laboratories, F. Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technology, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Large Outbreaks of Bacterial And Viral Epidemics in the World
4.2.2 Increasing Demand for Point-of-care Diagnostics
4.2.3 Recent Advancements in Pharmacogenomics
4.2.4 Rapidly Evolving Technology
4.3 Market Restraints
4.3.1 Limited Budgets for R&D and Economic Slowdown
4.3.2 Need for High-complexity Testing Centers
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Technology
5.1.1 In Situ Hybridization
5.1.2 Chips and Microarrays
5.1.3 Mass Spectrometry (MS)
5.1.4 Sequencing
5.1.5 PCR
5.1.6 Other Technologies
5.2 Application
5.2.1 Infectious Disease
5.2.2 Oncology
5.2.3 Pharmacogenomics
5.2.4 Microbiology
5.2.5 Genetic Disease Screening
5.2.6 Human Leukocyte Antigen Typing
5.2.7 Blood Screening
5.3 Product
5.3.1 Instruments
5.3.2 Reagents
5.3.3 Other Products
5.4 End User
5.4.1 Hospitals
5.4.2 Laboratories
5.4.3 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-la Roche Ltd
6.1.2 Illumina, Inc.
6.1.3 Hologic Corporation
6.1.4 Agilent Technologies / Dako
6.1.5 Qiagen
6.1.6 Myriad Genetics
6.1.7 BD (Becton, Dickinson And Company)
6.1.8 Abbott Laboratories
6.1.9 Cepheid Inc.
6.1.10 Genomic Health Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Technology
In Situ Hybridization
Chips and Microarrays
Mass Spectrometry (MS)
Sequencing
PCR
Other Technologies
Application
Infectious Disease
Oncology
Pharmacogenomics
Microbiology
Genetic Disease Screening
Human Leukocyte Antigen Typing
Blood Screening
Product
Instruments
Reagents
Other Products
End User
Hospitals
Laboratories
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Middle East & Africa Glucagon-like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 13-06-2019
Market Overview
For the last three decades, the Middle East & African countries have witnessed some critical social and economic transformations, which involve rapid economic growth and urbanization, along with reduced infant mortality and increased life expectancy.
Meanwhile, a few countries in the region have seen a decreased economy, due to political tension, along with other social factors, such as terrorism.
In the Middle East & Africa, approximately 35.5 million people live with diabetes. Middle Eastern countries have a high diabetes prevalence.
For instance, the percentages of type 2 diabetes in a few important countries are as follows: Saudi Arabia 24%, Kuwait 23%, Bahrain 22%, Qatar 20%, and UAE 19%.
It is estimated that only USD 17 billion was spent on diabetes, despite high prevalence in the region. Growth in the number of middle-class households, as well as increasing per capita income in these countries, will result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
Along with this, a few important factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.
The Middle East & Africa region suffers from a high burden of diabetes, and its adverse health and economic consequences. The disease should be viewed as a serious threat, not just from public health, but also from a development perspective. With risk factors, such as increasing obesity, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries in the region. It is one of the most common chronic diseases in Saudi Arabia, followed by Kuwait.
Scope of the Report
The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends –
Rising Prevalence of Diabetes
As per a WHO report, the global prevalence of diabetes, among people of over 18 years, has accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
Statistics prove that one in ten individuals in the country has diabetes and a rise in this trend is expected to take the situation to one in three, by 2050 (according to the Center for Disease Control and Prevention).
The growing prevalence of diabetes is the primary driver for the global diabetes care drugs market. Additionally, raising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.
Saudi Arabia to Lead the GLP-1 Market
The GLP-1 market is expected to witness a high CAGR, of 13.4%, over the forecast period. Saudi Arabia is expected to hold the highest market share in the Middle East & Africa GLP-1 agonist market.
Victoza holds the highest market share in the region and the same trend is seen in Saudi Arabia. Trulicity is expected to have the highest growth during the forecast period (2019-2024)
The Saudi Arabian market is expected to see robust growth during the forecast period (2019-2024), due to the high number of R&D-related investments in the market. Some of these pipeline products are two of Sanofi’s GLP-1s, efpeglenatide and SAR425899, which are expected to launch in 2020 and 2021, respectively.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding their presence in all regions.
The market for GLP-1 agonist drugs includes Victoza, Trulicity, Byetta, Bydureon, and Lyxumia. The market is expected to grow significantly, during the forecast period, due mainly to Trulicity and Ozempic.
Oral Semaglutide, which is in phase 3 of its clinical trials, is expected to launch by 2020. The product has shown better results than Januvia in studies.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 Middle East & Africa
5.2.1.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Egypt (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Iran (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.4 South Africa (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 Oman (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
Middle East & Africa
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Egypt (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Iran (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Oman (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Middle East & Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)